Business Wire

CA-CEPTON-TECHNOLOGIES

2.3.2021 14:02:09 CET | Business Wire | Press release

Share
Red Fox ID and Cepton Enable Barrier-Free, High-Speed Tolling Worldwide With High Performance Lidar Based Solutions

A state-of-the art electronic tolling system that utilizes high-performance lidar sensors from Cepton and a cutting-edge vehicle identification solution from Red Fox ID is expected to be deployed on a major highway turnpike crossing multiple states in the United States, thereby promising fast, highly accurate, barrier-free, real-time tolling to enable smooth traffic flows. This marks the maturing of the deep partnership between Cepton and Red Fox ID in bringing innovative, automated tolling solutions to major customers across North America, EMEA and Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005524/en/

Based on an extended collaboration with leading lidar solution provider Cepton, Red Fox ID – a leading designer and developer of vehicle identification and classification solutions - has developed a multi-lane, free flow tolling system called Quantum , which is able to accurately detect, track and classify vehicles of any size or type at highway speeds. Quantum uses Cepton’s Micro Motion Technology (MMT® ) based Sora™-P60 or Sora™-P90 lidar sensors for high-resolution vehicle profiling, to enable integrators and road operators to achieve highly accurate customer billing in real time, with free flow, barrier-free tolling.

For tolls to be charged correctly based on vehicle class, traditional tolling systems often use tollbooths for manual processing or depend on vehicle speed reduction infrastructure to allow for time to capture vehicle information. That can cause congestion, increased emissions and frustration amongst customers. More advanced systems that aim to enable faster tolling, however, are often subject to significant errors, such as missed vehicles or wrong vehicle classification, due to known limitations of the sensors currently being used, such as cameras and weight-based ground sensors. Vehicle classification errors can have significant operating cost consequences for tolling operators while leakage leads to lower revenues. With tollways processing tens of millions of vehicles a year, the cumulative impact of inaccuracies and errors creates significant administrative costs, losses and customer dissatisfaction.

Red Fox ID’s Quantum solution addresses such challenges by adding an extra layer of accuracy to the tolling system by integrating Cepton’s unique lidar technology. A gantry-mounted system using Quantum is therefore able to accurately detect and track vehicles, even as they switch lanes. The lidar-enabled Quantum solution captures and extracts high quality information, such as vehicle velocity, size and class. All of that information is used as input to a separate billing system to compute and apply the appropriate tolling charge. Quantum can also direct camera-based systems on the gantry to capture a vehicle’s front and rear plates in the event that a transponder cannot be detected. Through these innovations, Quantum has demonstrated a vehicle detection accuracy in all traffic conditions of 99.96%, an axle classification accuracy in all traffic conditions of 99.9% and a vehicle length accuracy of +/-5%. This world-class performance is enabled by Cepton’s innovative Sora-P sensor family which has been tested and proven during extended trials, including in various weather and light conditions.

The recently released Sora-P90 lidar features an industry-leading 380 Hz frame rate to deliver 1140 line scans per second, providing high-fidelity profiling of vehicles passing at highway speeds . Powered by Cepton’s patented, rotation-free, frictionless and mirrorless MMT® , the Sora-P90 is rugged, reliable and scalable, making it ideally suited for automated tolling applications. In addition, with its 90° horizontal field of view, the lidar can be set up using one gantry instead of requiring two separate sensors and gantries, making overall deployment more cost effective for tolling system integrators.

With their unparalleled experienced in building innovative tolling solutions, and deep understanding of the industry trend away from ground loop-based tolling systems towards next-generation gantry-based overhead systems powered by advanced sensor technologies, Red Fox ID has been working with Cepton on multiple trials and proof of concept projects across the globe since 2019. This has allowed both partners to expand the application of advanced lidar intelligence for high accuracy tolling on highways and roadways in a growing list of countries, across North America, EMEA and Asia.

Steve Bird, CEO of Red Fox ID, said: “Our industry’s drive for overhead tolling solutions has failed to materialize in the mainstream due, primarily, to a lack of sensors capable of achieving the high levels of accuracy required for a modern tolling product. The technical innovations enabled by Cepton offers us new design options. Improvements in the resolution of the data, the ability to deal with the full range of weather-related conditions, and the development of a sensor with an in-service lifespan suitable for tolling make it possible, for the first time, for us to develop an accurate, overhead free flow system. Our partnership with Cepton will be a game-changer in revolutionizing the tolling market.”

Dr. Jun Pei, CEO of Cepton, added: “It is very clear that lidar’s uses extend far beyond just serving as the ‘eyes’ of autonomous vehicles. Our lidar technology has a huge part to play in making our transport infrastructure smarter, safer, greener and more efficient, as we can see here following Quantum’s highly successful real-world testing. The key to success for toll operators and providers is minimal error and maximum yield, and we are excited to be partnering with Red Fox ID to help our mutual customers achieve this goal with our market-leading lidar technology. We look forward to working with them to expand our partnership worldwide.”

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .

About Red Fox ID Limited

Red Fox ID is a technology provider, primarily for the global tolling market and also for the broader ITS markets.

A company with over 3 decades of proven experience in the delivery of innovative, forward looking and industry leading solutions for the world of all weather, multi-lane, free-flow automatic vehicle detection and classification (AVDC). System integrators, toll authorities and road operators select Red Fox ID for their experience in advance sensor integration and expertise in road side tolling systems, from the software to the road side Red Fox ID has domain experts that ensure timely delivery of the industries most accurate AVDC system.

For more information visit www.redfoxid.co.uk or contact us at sales@redfoxid.co.uk or call +44 7866845819.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye